Huapont Pharmaceutical Invests 86 M Yuan In Nutrichem Laboratory
This article was originally published in PharmAsia News
Chongqing Huapont Pharmaceutical has confirmed that it is injecting 86 million yuan into Beijing Nutrichem Laboratory to become the latter's second largest shareholder. According to the agreement, Nutrichem Laboratory and its related enterprises Shangyu Nutrichem and Nutrichem International will reorganize to come under Huapont. Industry analysts observed that Huapont was attracted by the promising market of Nutrichem Laboratory's products as well as their common background on chiral drug research. The complementary strengths of both companies will help expand their chiral drug business. (Click here for more)
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Erectile problems prevent a quarter of Brits from being intimate with a partner. Viatris' Upjohn - which markets Viagra Connect in the UK - is working with the Men’s Health Forum, sexual health charity Brook and dating expert Sarah Louise Ryan raise awareness of the problem and get men talking about the issue with their partners and with healthcare professionals.
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.